Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.33 |
| ▸ | WNT1 | P04628 | 3/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16608483 | 0.92 | CHUK (0.40) | DGAT1CHUKAXLTYRO3MERTK | |
| SCHEMBL16608578 | 0.90 | DGAT1 (0.35) | DGAT1CHUKAXLTYRO3MERTK | |
| SCHEMBL20193156 | 0.89 | GSK3B (0.33) | GSK3BDYRK1AWNT1CHUKTYK2 | |
| SCHEMBL20191329 | 0.89 | DGAT1 (0.35) | DGAT1GSK3BDYRK1AWNT1CHUK | |
| SCHEMBL20191330 | 0.89 | CHUK (0.33) | DGAT1CHUKAXLTYRO3MERTK | |
| SCHEMBL16608283 | 0.86 | DGAT1 (0.33) | DGAT1CHUKAXLTYRO3MERTK | |
| SCHEMBL16608387 | 0.85 | DGAT1 (0.32) | DGAT1CHUKAXLTYRO3MERTK | |
| SCHEMBL18013730 | 0.84 | GPR119 (0.35) | DGAT1DYRK1ACHUK | |
| SCHEMBL16608300 | 0.84 | CHUK (0.54) | CHUK | |
| SCHEMBL16608650 | 0.83 | GPR119 (0.40) | CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981963-B2 | 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| EP-3049412-B1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-08-11 | — | — | US | disclosed |
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-08-11 | — | — | US | disclosed |
| WO-2015044269-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229851-A1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K13 | DGAT1 2685/4885GSK3B 573/4885DYRK1A 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.